Winstanley PA - Search Results

1

Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Edwards G, Winstanley PA, Ward SA. Edwards G, et al. Among authors: winstanley pa. Clin Pharmacokinet. 1994 Aug;27(2):150-65. doi: 10.2165/00003088-199427020-00006. Clin Pharmacokinet. 1994. PMID: 7955777 Review.

2

Malaria chemotherapy.

Winstanley P, Ward S. Winstanley P, et al. Adv Parasitol. 2006;61:47-76. doi: 10.1016/S0065-308X(05)61002-0. Adv Parasitol. 2006. PMID: 16735162 Review.

3

Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Winstanley P, Ward S, Snow R, Breckenridge A. Winstanley P, et al. Clin Microbiol Rev. 2004 Jul;17(3):612-37, table of contents. doi: 10.1128/CMR.17.3.612-637.2004. Clin Microbiol Rev. 2004. PMID: 15258096 Free PMC article. Review.

4

Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.

Bell DJ, Nyirongo SK, Mukaka M, Zijlstra EE, Plowe CV, Molyneux ME, Ward SA, Winstanley PA. Bell DJ, et al. Among authors: winstanley pa. PLoS One. 2008 Feb 13;3(2):e1578. doi: 10.1371/journal.pone.0001578. PLoS One. 2008. PMID: 18270569 Free PMC article. Clinical Trial.

5

Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure.

Ochong E, Bell DJ, Johnson DJ, D'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA, Owen A. Ochong E, et al. Among authors: winstanley pa. Antimicrob Agents Chemother. 2008 Nov;52(11):3883-8. doi: 10.1128/AAC.00431-08. Epub 2008 Aug 25. Antimicrob Agents Chemother. 2008. PMID: 18725445 Free PMC article.

6

Clinical status and implications of antimalarial drug resistance.

Winstanley PA, Ward SA, Snow RW. Winstanley PA, et al. Microbes Infect. 2002 Feb;4(2):157-64. doi: 10.1016/s1286-4579(01)01523-4. Microbes Infect. 2002. PMID: 11880047 Free article.

7

Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis.

Winstanley P, Khoo S, Szwandt S, Edwards G, Wilkins E, Tija J, Coker R, McKane W, Beeching N, Watkin S, et al. Winstanley P, et al. J Antimicrob Chemother. 1995 Aug;36(2):435-9. doi: 10.1093/jac/36.2.435. J Antimicrob Chemother. 1995. PMID: 8522475 Clinical Trial.

8

The disposition of amodiaquine in Zambians and Nigerians with malaria.

Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, Orme ML, Breckenridge AM. Winstanley PA, et al. Br J Clin Pharmacol. 1990 Jun;29(6):695-701. doi: 10.1111/j.1365-2125.1990.tb03690.x. Br J Clin Pharmacol. 1990. PMID: 2378788 Free PMC article.

9

Effect of dose size on amodiaquine pharmacokinetics after oral administration.

Winstanley PA, Edwards G, Orme ML, Breckenridge AM. Winstanley PA, et al. Eur J Clin Pharmacol. 1987;33(3):331-3. doi: 10.1007/BF00637573. Eur J Clin Pharmacol. 1987. PMID: 3691624 Clinical Trial.

10

Disposition of intravenous pyrimethamine in healthy volunteers.

Almond DS, Szwandt IS, Edwards G, Lee MG, Winstanley PA. Almond DS, et al. Among authors: winstanley pa. Antimicrob Agents Chemother. 2000 Jun;44(6):1691-3. doi: 10.1128/AAC.44.6.1691-1693.2000. Antimicrob Agents Chemother. 2000. PMID: 10817730 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters